Topotecan (Hycamtin) in the treatment of lung cancer and other solid tumorsPEREZ-SOLER, Roman.Seminars in oncology. 1997, Vol 24, Num 6, issn 0093-7754, 64 p., SUP20Serial Issue

Cutaneous adverse effects with HER1/EGFR-targeted agents : Is there a silver lining?PEREZ-SOLER, Roman; SALTZ, Leonard.Journal of clinical oncology. 2005, Vol 23, Num 22, pp 5235-5246, issn 0732-183X, 12 p.Article

Topotecan in advanced colorectal cancerCREEMERS, G. J.Seminars in oncology. 1997, Vol 24, Num 6, pp S20.42-S20.48, issn 0093-7754, SUP20Article

Topotecan in the treatment of non-small cell lung cancerPEREZ-SOLER, R.Seminars in oncology. 1997, Vol 24, Num 6, pp S20.34-S20.41, issn 0093-7754, SUP20Article

Targeting Angiogenesis in Squamous Non-Small Cell Lung CancerPIPERDI, Bilal; MERLA, Amartej; PEREZ-SOLER, Roman et al.Drugs (Basel). 2014, Vol 74, Num 4, pp 403-413, issn 0012-6667, 11 p.Article

The potential role of topotecan in the treatment of advanced breast cancerCHANG, A. Y.Seminars in oncology. 1997, Vol 24, Num 6, pp S20.49-S20.54, issn 0093-7754, SUP20Article

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer: Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor PatientsPIPERDI, Bilal; PEREZ-SOLER, Roman.Drugs (Basel). 2012, Vol 72, pp 11-19, issn 0012-6667, 9 p., SUP1Article

Review of phase I clinical studies with topotecanROWINSKY, E. K; VERWEIJ, J.Seminars in oncology. 1997, Vol 24, Num 6, pp S20.3-S20.10, issn 0093-7754, SUP20Article

Mechanisms of Resistance to Vascular Endothelial Growth Factor BlockadeABDULLAH, Shaad E; PEREZ-SOLER, Roman.Cancer. 2012, Vol 118, Num 14, pp 3455-3467, issn 0008-543X, 13 p.Article

Skin toxicities associated with epidermal growth factor receptor inhibitorsTIANHONG LI; PEREZ-SOLER, Roman.Targeted oncology. 2009, Vol 4, Num 2, pp 107-119, issn 1776-2596, 13 p.Article

Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinibLING, Yi-He; TIANHONG LI; PEREZ-SOLER, Roman et al.Cancer chemotherapy and pharmacology. 2009, Vol 64, Num 3, pp 539-548, issn 0344-5704, 10 p.Article

Topotecan in the treatment of gynecologic cancerCOLEMAN, R. L; MILLER, D. S.Seminars in oncology. 1997, Vol 24, Num 6, pp S20.55-S20.63, issn 0093-7754, SUP20Article

Topotecan in combination chemotherapyROWINSKY, E. K; KAUFMANN, S. H.Seminars in oncology. 1997, Vol 24, Num 6, pp S20.11-S20.26, issn 0093-7754, SUP20Article

The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and CetuximabPEREZ-SOLER, Roman; YIYU ZOU; TIANHONG LI et al.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6766-6777, issn 1078-0432, 12 p.Article

Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublinesLING, Yi-He; DONATO, Nicholas J; PEREZ-SOLER, Roman et al.Cancer chemotherapy and pharmacology. 2001, Vol 47, Num 6, pp 473-480, issn 0344-5704Article

Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft modelsLING, Yi-He; ARACIL, Miguel; JIMENO, José et al.European journal of cancer (1990). 2009, Vol 45, Num 10, pp 1855-1864, issn 0959-8049, 10 p.Article

Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasisLIANG HU; MERLIN LEE; CAMPBELL, Wendy et al.Blood. 2004, Vol 104, Num 9, pp 2746-2751, issn 0006-4971, 6 p.Article

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cellsTIANHONG LI; LING, Yi-He; GOLDMAN, I. David et al.Clinical cancer research. 2007, Vol 13, Num 11, pp 3413-3422, issn 1078-0432, 10 p.Article

p53 aerosol formulation with low toxicity and high efficiency for early lung cancer treatmentYIYU ZOU; TORNOS, Carmen; XUAN QIU et al.Clinical cancer research. 2007, Vol 13, Num 16, pp 4900-4908, issn 1078-0432, 9 p.Article

Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicityYUN ZHONG; DELGADO, Yara; GOMEZ, Jorge et al.Clinical cancer research. 2001, Vol 7, Num 6, pp 1683-1687, issn 1078-0432Article

Cell cycle inhibitors for the treatment of NSCLCSHCHERBA, Marina; YUANXIN LIANG; FERNANDES, David et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 7, pp 991-1004, issn 1465-6566, 14 p.Article

Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expressionYUN ZHONG; LOPEZ-BARCONS, Lluis; HAIGENTZ, Missak JR et al.International journal of oncology. 2004, Vol 24, Num 6, pp 1573-1579, issn 1019-6439, 7 p.Article

The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancerPEREZ-SOLER, Roman.Clinical cancer research. 2004, Vol 10, Num 12, pp 4238s-4240s, issn 1078-0432, 2Conference Paper

Treatment of Non-Small-Cell Lung Cancer with Erlotinib or GefitinibCATALDO, Vince D; GIBBONS, Don L; PEREZ-SOLER, Román et al.The New England journal of medicine. 2011, Vol 364, Num 10, pp 947-955, issn 0028-4793, 9 p.Article

Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell linesQUN DAI; LING, Yi-He; LIA, Marie et al.Clinical cancer research. 2005, Vol 11, Num 4, pp 1572-1578, issn 1078-0432, 7 p.Article